BFM
RLMD icon

Boothbay Fund Management’s Relmada Therapeutics RLMD Stock Holding History

Boothbay Fund Management’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-136,500
Closed -$5.05M – 2387
2022
Q3 		$5.05M Buy
136,500
+100,100
+275% +$2.77M 0.13% 191
2022
Q2 		$691K Buy
+36,400
New +$794K 0.02% 1002

Other funds holding RLMD

JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JHC
Jones Hill Capital New York $470M AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Boothbay Fund Management's RLMD Position: Q2 2026 in Review

Boothbay Fund Management reduced its Relmada Therapeutics (RLMD) stake by 23% in Q2 2026, selling an estimated $1.15M and leaving 564,759 shares worth $3.91M. The position accounts for 0.05% of the portfolio, ranked #427.

Boothbay Fund Management first reported a position in RLMD in Q1 2021 and has held it in 9 quarters since. The position peaked at $5.07M in Q1 2026. 126 funds tracked by Wall St. Rank hold RLMD as of Q2 2026.

  • Boothbay Fund Management held 564,759 shares of Relmada Therapeutics worth $3.91M as of Q2 2026.
  • Boothbay Fund Management sold 164,296 Relmada Therapeutics shares in Q2 2026, an estimated $1.15M.
  • Relmada Therapeutics made up 0.05% of Boothbay Fund Management's portfolio in Q2 2026, its #427 holding.
  • Boothbay Fund Management first reported a position in Relmada Therapeutics in Q1 2021 and has held it in 9 quarters since.
  • Boothbay Fund Management's Relmada Therapeutics position peaked at $5.07M in Q1 2026.
  • 126 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q2 2026.

Based on Boothbay Fund Management's 13F filing for Q2 2026, filed 14 Aug 2026.